Detection of hypofibrinolysis in stable coronary artery disease using the overall haemostatic potential assay

Thrombosis Research

Volumn 131, Issue 5, 2013, Pages 457-462

  Reddel, Caroline J ^a   Curnow, Jennifer L ^a,b   Voitl, Jasmin ^a   Rosenov, Alexander ^a   Pennings, Gabrielle J ^a   Morel Kopp, Marie Christine ^c,d   Brieger, David B ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ANZAC Research Institute   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Coronary artery disease; fibrinolysis; overall haemostatic potential; thrombin generation

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIFIBRINOLYTIC AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; FIBRIN; NITRATE; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING DISORDER; CARDIAC PATIENT; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART INFARCTION; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; HYPOFIBRINOLYSIS; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; STABLE ANGINA PECTORIS; THROMBOCYTE; THROMBOCYTE POOR PLASMA;

AGED; AGED, 80 AND OVER; BLOOD COAGULATION; CORONARY ARTERY DISEASE; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; THROMBIN;

EID: 84877731287     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2013.03.015     Document Type: Article

References (29)

1. M.J. Davies Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995 Circulation 94 1996 2013 2020
2. R.H. Mehta, E. Bossone, and K.A. Eagle Current concepts in secondary prevention after acute myocardial infarction Herz 25 2000 47 60
3. F. Ottani, and M. Galvani Prognostic role of hemostatic markers in acute coronary syndromes patients Clin Chim Acta 311 2001 33 39
4. M. Stegnar, N. Vene, and M. Bozic Do haemostasis activation markers that predict cardiovascular disease exist? Pathophysiol Haemost Thromb 33 2003 302 308
5. D.A. Gorog Prognostic value of plasma fibrinolysis activation markers in cardiovascular disease J Am Coll Cardiol 55 2010 2701 2709
6. M.E. Meltzer, C.J. Doggen, P.G. de Groot, F.R. Rosendaal, and T. Lisman Plasma levels of fibrinolytic proteins and the risk of myocardial infarction in men Blood 116 2010 529 536
7. K. Breddin, D. Loew, K. Lechner, K. Oberla, and E. Walter The German-Austrian aspirin trial: a comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. On behalf of the German-Austrian Study Group Circulation 62 1980 V63 V72
8. P. Smith, H. Arnesen, and I. Holme The effect of warfarin on mortality and reinfarction after myocardial infarction N Engl J Med 323 1990 147 152
9. A. Meijer, F.W. Verheugt, C.J. Werter, K.I. Lie, J.M. van der Pol, and M.J. van Eenige Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographic study. Results of the APRICOT Study Circulation 87 1993 1524 1530
10. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group Lancet 343 1994 499 503
11. T.W. Barrowcliffe, M. Cattaneo, G.M. Podda, P. Bucciarelli, F. Lussana, and A. Lecchi New approaches for measuring coagulation Haemophilia 12 Suppl. 3 2006 76 81
12. A. Tripodi, V. Chantarangkul, and P.M. Mannucci Acquired coagulation disorders: revisited using global coagulation/anticoagulation testing Br J Haematol 147 2009 77 82
13. J. Orbe, M. Zudaire, R. Serrano, I. Coma-Canella, S. Martinez de Sizarrondo, and J.A. Rodriguez Increased thrombin generation after acute versus chronic coronary disease as assessed by the thrombin generation test Thromb Haemost 99 2008 382 387
14. S. He, K. Bremme, and M. Blomback A laboratory method for determination of overall haemostatic potential in plasma. I. Method design and preliminary results Thromb Res 96 1999 145 156
15. K. Leander, M. Blomback, H. Wallen, and S. He Impaired fibrinolytic capacity and increased fibrin formation associate with myocardial infarction Thromb Haemost 107 2012 1092 1099
16. J.L. Curnow, M.C. Morel-Kopp, and C.M. Ward Analysis of the sensitivity of the Overall Haemostatic Potential (OHP) assay to coagulation factors J Thromb Haemost 5 Suppl. 2 2007 [P-S-136]
17. S. He, A. Antovic, and M. Blomback A simple and rapid laboratory method for determination of haemostasis potential in plasma. II. Modifications for use in routine laboratories and research work Thromb Res 103 2001 355 361
18. J.L. Curnow, M.C. Morel-Kopp, C. Roddie, M. Aboud, and C.M. Ward Reduced fibrinolysis and increased fibrin generation can be detected in hypercoagulable patients using the overall hemostatic potential assay J Thromb Haemost 5 2007 528 534
19. H.C. Hemker, P. Giesen, R. AlDieri, V. Regnault, E. de Smed, and R. Wagenvoord The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability Pathophysiol Haemost Thromb 32 2002 249 253
20. K. Brummel-Ziedins, A. Undas, T. Orfeo, M. Gissel, S. Butenas, and K. Zmudka Thrombin generation in acute coronary syndrome and stable coronary artery disease: dependence on plasma factor composition J Thromb Haemost 6 2008 104 110
21. A. Undas, K. Szuldrzynski, K.E. Brummel-Ziedins, W. Tracz, K. Zmudka, and K.G. Mann Systemic blood coagulation activation in acute coronary syndromes Blood 113 2009 2070 2078
22. M.E. Meltzer, C.J. Doggen, P.G. de Groot, F.R. Rosendaal, and T. Lisman Reduced plasma fibrinolytic capacity as a potential risk factor for a first myocardial infarction in young men Br J Haematol 145 2009 121 127
23. M. Skeppholm, A. Kallner, K. Malmqvist, M. Blomback, and H. Wallen Is fibrin formation and thrombin generation increased during and after an acute coronary syndrome? Thromb Res 128 2011 483 489
24. E. Zorio, J. Gilabert-Estelles, F. Espana, L.A. Ramon, R. Cosin, and A. Estelles Fibrinolysis: the key to new pathogenetic mechanisms Curr Med Chem 15 2008 923 929
25. R.D. Eastham, and E.H. Morgan Plasma-Fibrinogen Levels in Coronary-Artery Disease Lancet 2 1963 1196 1197
26. J.J. Stec, H. Silbershatz, G.H. Tofler, T.H. Matheney, P. Sutherland, and I. Lipinska Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population Circulation 102 2000 1634 1638
27. E. Stepien, D. Plicner, A. Branicka, E. Stankiewicz, A. Pazdan, and M. Sniezek-Maciejewska Factors influencing thrombin generation measured as thrombin-antithrombin complexes levels and using calibrated automated thrombogram in patients with advanced coronary artery disease Pol Arch Med Wewn 117 2007 297 305
28. J.L. Mega, E. Braunwald, S.D. Wiviott, J.P. Bassand, D.L. Bhatt, and C. Bode Rivaroxaban in patients with a recent acute coronary syndrome N Engl J Med 366 2012 9 19
29. F. Andreotti, L. Testa, G.G. Biondi-Zoccai, and F. Crea Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients Eur Heart J 27 2006 519 526